GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (NAS:CMPS) » Definitions » ROA %

Compass Pathways (Compass Pathways) ROA %

: -45.26% (As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Compass Pathways's annualized Net Income for the quarter that ended in Dec. 2023 was $-130.13 Mil. Compass Pathways's average Total Assets over the quarter that ended in Dec. 2023 was $287.51 Mil. Therefore, Compass Pathways's annualized ROA % for the quarter that ended in Dec. 2023 was -45.26%.

The historical rank and industry rank for Compass Pathways's ROA % or its related term are showing as below:

CMPS' s ROA % Range Over the Past 10 Years
Min: -66.74   Med: -50.08   Max: -28.45
Current: -51.26

During the past 6 years, Compass Pathways's highest ROA % was -28.45%. The lowest was -66.74%. And the median was -50.08%.

CMPS's ROA % is ranked worse than
87.99% of 666 companies
in the Healthcare Providers & Services industry
Industry Median: 1.235 vs CMPS: -51.26

Compass Pathways ROA % Historical Data

The historical data trend for Compass Pathways's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Premium Member Only -66.74 -51.16 -28.45 -36.73 -50.06

Compass Pathways Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.65 -52.26 -59.16 -52.49 -45.26

Competitive Comparison

For the Medical Care Facilities subindustry, Compass Pathways's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compass Pathways ROA % Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's ROA % distribution charts can be found below:

* The bar in red indicates where Compass Pathways's ROA % falls into.



Compass Pathways ROA % Calculation

Compass Pathways's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-118.464/( (197.294+275.987)/ 2 )
=-118.464/236.6405
=-50.06 %

Compass Pathways's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-130.128/( (299.033+275.987)/ 2 )
=-130.128/287.51
=-45.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Compass Pathways  (NAS:CMPS) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-130.128/287.51
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-130.128 / 0)*(0 / 287.51)
=Net Margin %*Asset Turnover
=N/A %*0
=-45.26 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Compass Pathways ROA % Related Terms

Thank you for viewing the detailed overview of Compass Pathways's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Compass Pathways (Compass Pathways) Business Description

Traded in Other Exchanges
Address
33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Executives
Ekaterina Malievskaia officer: Chief Innovation Officer C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
George Jay Goldsmith director, 10 percent owner, officer: Chief Executive Officer C/O COMPASS PATHWAYS PLC, 1 ASHLEY ROAD, 3RD FLOOR, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Mary-rose Hughes officer: Interim CFO C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F0DQ
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Kabir Nath director, officer: Chief Executive Officer C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F 0DQ
Annalisa Jenkins director C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
David Y Norton director 8 GREENHOLM STREET, APT C, PRINCETON NJ 08540
Matthew A Owens officer: General Counsel & CLO 1900 POLARIS PARKWAY, COLUMBUS OH 43240
Atai Life Sciences Ag 10 percent owner KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v. 10 percent owner 524 BROADWAY, NEW YORK NY 10013
Linda Mcgoldrick director C/O AVADIM HEALTH, INC., 81 THOMPSON STREET, ASHEVILLE NC 28803
Jason Camm director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Robert Mcquade director C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Michael Falvey officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Guy Goodwin officer: Chief Medical Officer C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT